In Re: Zofran (Ondansetron)Products Liability Litigation

Track this case

Case overview

Case Number:

1:15-md-02657

Court:

Massachusetts

Nature of Suit:

Personal Injury: Health Care/Pharmaceutical Personal Injury Product Liability

Multi Party Litigation:

Multi-district Litigation

Judge:

F. Dennis Saylor, IV

Firms

Companies

Glenmark Pharmaceuticals Ltd.

Sectors & Industries:

Healthcare
- Generic

January 18, 2018
GSK Says Families Too Late To Amend Zofran MDL

GlaxoSmithKline attorneys on Thursday blasted an attempt by hundreds of families who blame the company's widely prescribed antiemetic for unexpected birth defects to amend their lawsuits and loop in federal investigative materials produced during a year of discovery.
November 06, 2017
Families Want Zofran MDL Paused To Beef Up Suit

Families suing GlaxoSmithKline for allegedly marketing to pregnant women a nausea treatment linked to birth defects urged a Massachusetts federal judge Friday to pause a dismissal bid while they file an amended complaint reflecting more than 1 million pages of documents produced in the fourth phase of discovery.
August 25, 2017
Foreign Discovery Mostly Denied In Zofran Birth Defect MDL

A Massachusetts federal judge on Thursday mostly rejected efforts by families suing GlaxoSmithKline over alleged links between birth defects and anti-nausea drug Zofran to get access to foreign regulatory files.
July 28, 2017
Families In Zofran MDL Seek Docs About Foreign Regulators

Families suing GlaxoSmithKline over its alleged misrepresentations about links between its anti-nausea drug Zofran and birth defects asked a federal court overseeing the multidistrict litigation on Thursday to make the company turn over regulatory files from Japan, the United Kingdom and Canada.
May 08, 2017
GSK Seeks To Strike Fraud Claims In Zofran MDL

GlaxoSmithKline PLC on Monday asked a Massachusetts federal court to strike fraud-based claims about its marketing of anti-nausea drug Zofran from multidistrict litigation alleging that the drug is linked to birth defects, saying that it will be prejudiced if consumers are allowed to obtain discovery on those claims.
April 24, 2017
Judge Keeps Fraud Claims Against GSK Alive In Zofran MDL

A Massachusetts federal judge on Monday declined to nix fraud-based claims from multidistrict litigation alleging that GlaxoSmithKline PLC's anti-nausea drug Zofran is linked to birth defects, saying that claims about the drug's labeling are sufficiently specific to pass muster even though he found the suit's marketing-campaign allegations too broad.
January 26, 2017
GSK Says No Basis For Fraud Claims In Zofran MDL

GlaxoSmithKline plc asked a Massachusetts federal judge on Thursday to dismiss fraud-based claims from multidistrict litigation connecting the anti-nausea drug Zofran to birth defects, arguing that the master complaint is devoid of details about any alleged lies and obfuscations.
January 04, 2017
Families Hit Back At GSK'S Zofran Fraud Dismissal Bid

Plaintiffs in a multidistrict litigation against GlaxoSmithKline PLC told a Massachusetts federal court Tuesday that they adequately set out off-label fraud claims in master complaints linking the anti-nausea drug Zofran to birth defects.
November 10, 2016
Judge Will Hear GSK's Arguments To Dismiss Zofran MDL

A Boston federal judge said Thursday that he would hear GlaxoSmithKline's arguments on dismissing some cases and claims from multidistrict litigation linking the anti-nausea drug Zofran to birth defects, overruling the objections of the plaintiffs.
October 14, 2016
GSK Wants Fraud Claims Dismissed In Zofran MDL

GlaxoSmithKline PLC on Thursday told a Massachusetts federal court that it shouldn't have to face fraud claims in multidistrict litigation over an alleged off-label marketing scheme for its anti-nausea drug Zofran, because the suits don't sufficiently outline the details of the alleged misconduct.